OpenDNA (CardioRisk+, CancerRisk+, TotalRisk+, PolyRisk+)

by OpenDNA  · Based in Israel → — unknown
Cardiology genetics Internal Medicine
Website
Claim this tool
Is this the maker? Claim the company →

Overview

OpenDNA aimed to provide advanced AI-driven risk assessment tools designed to integrate genetic insights with clinical data. Their suite of products, including CardioRisk+, CancerRisk+, TotalRisk+, and PolyRisk+, were intended to offer physicians actionable insights for predicting, preventing, and personalizing treatment strategies for a range of complex diseases.

The core value proposition was to empower healthcare providers with a deeper understanding of individual patient risk profiles, moving beyond traditional risk factors to incorporate genetic predispositions. This approach sought to enable more proactive and tailored interventions, potentially improving patient outcomes and optimizing resource allocation.

The tools were envisioned to support various clinical applications, from identifying individuals at high risk for cardiovascular disease or specific cancers to providing a comprehensive, multi-disease risk assessment. By leveraging AI, OpenDNA aimed to simplify the interpretation of complex genetic and clinical data, making it accessible and actionable for physicians in their daily practice.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Key Features

  • AI-driven risk assessment
  • Genetic data integration
  • Clinical data integration
  • Personalized treatment insights
  • Disease prediction
  • Preventive care recommendations
  • Cardiovascular risk assessment (CardioRisk+)
  • Cancer risk assessment (CancerRisk+)
  • Multi-disease risk assessment (TotalRisk+, PolyRisk+)

Use Cases

  • Identifying high-risk patients for proactive intervention
  • Personalizing treatment plans based on genetic and clinical data
  • Enhancing preventive care strategies
  • Supporting diagnostic processes for complex diseases
  • Optimizing patient management in cardiology and oncology
  • Educating patients on their individual disease risks

What Physicians Need to Know

Heart Failure Risk Prediction
OpenDNA's CardioRisk+ is an AI-powered tool that assesses cardiovascular risk, including heart attack, diabetes, hypertension, high cholesterol, obesity, atrial fibrillation (AF), chronic kidney disease (CKD), metabolic dysfunction-associated steatotic liver disease (MASLD), and venous thromboembolism (VTE). It combines polygenic risk scores (PRS) with clinical data for earlier and more accurate risk detection. Studies show that by identifying high-risk individuals early through genetic and clinical risk assessment, proactive prevention strategies can be enabled. The AI model has demonstrated superior performance in predicting coronary heart disease (CHD) events compared to traditional methods like the Pooled Cohort Equations (PCE), with an AUC of 0.69 vs. 0.67, further enhanced to 0.74 with the inclusion of Coronary Artery Calcium (CAC) scores. The model achieved 80% sensitivity, 100% negative predictive value (NPV), and a 22.54% net reclassification improvement (NRI) when combined with CAC.
Coronary Artery Assessment
OpenDNA's AI model for coronary heart disease risk prediction has shown enhanced accuracy when integrated with Coronary Artery Calcium (CAC) scores. This combined approach achieved an AUC of 0.74, outperforming the PCE alone. The AI model was also more strongly associated with the CAC score (p=0.003) than the PCE (p=0.041). This integration helps in early CHD risk stratification, particularly for individuals where traditional scores might overlook risk.
Cardiac Monitoring Integration
OpenDNA's platform is designed for seamless integration into Electronic Medical Records (EMRs), allowing for automated data pull and real-time interactive decision support. This integration facilitates quick and easy workflows for test ordering, automatic data entry, and single sign-on. The interactive dashboards can also be shared with patients.
AHA/ACC Guideline Alignment
OpenDNA's AI-powered model for coronary heart disease risk prediction has been compared to the ACC ASCVD model, demonstrating higher sensitivity (0.511 vs. 0.346) and comparable specificity (0.863 vs. 0.866) at the 7.5% risk threshold. The Net Reclassification Index (NRI) improved by 13.79%, emphasizing the model's accuracy and alignment. A collaborative project with Mayo Clinic showcasing this AI-powered model was presented at the American College of Cardiology (ACC) conference.
Real-Time Alert Capability
OpenDNA's platform provides Gen AI-Based Decision Support, offering real-time, actionable insights. The system is designed to provide actionable recommendations for personalized prevention and treatment. Interactive 'what-if' dashboards allow clinicians and patients to adjust risk factors in real time to visualize the impact on lifetime risk, promoting shared decision-making and personalized prevention strategies.
Physician Tip

Leverage OpenDNA's AI-powered genetic risk assessments (CardioRisk+, CancerRisk+, TotalRisk+, PolyRisk+) to move beyond traditional risk models and gain earlier, more accurate insights into patient predispositions for various complex diseases. Integrate these tools into your clinical workflow for real-time decision support and personalized prevention strategies. Utilize the interactive 'what-if' dashboards to engage patients in understanding their risk factors and the potential impact of lifestyle modifications or interventions. Consider combining genetic insights with imaging data, such as CAC scores, for enhanced cardiovascular risk stratification, especially in early middle-aged adults where traditional scores might be less sensitive. The physician-ordered nature of these tests ensures that interpretation and integration into care plans are guided by medical professionals.

OpenDNA's patented platform is designed for seamless integration into Electronic Medical Records (EMRs). This integration supports automated data pull, single sign-on, and full integration of interactive dashboards, streamlining workflows for test ordering and data entry. The platform provides Gen AI-Based Decision Support directly within the clinical workflow, offering real-time, actionable insights and personalized recommendations. Interactive patient engagement tools, including 'what-if' risk modeling scenarios, are also integrated to empower both clinicians and patients.

Details

Category Cardiology AI, Clinical Decision Support & Reference, Oncology AI
Pricing Unknown — unknown
Compliance
BAA AvailableUnknown AI-estimated
HIPAA Compliant Yes AI-estimated
FDA Status Unknown AI-estimated — unknown
Integrations
EHR Not specified
Specialties Cardiology, Genetics, Internal Medicine, Oncology, Preventive Medicine

Social Proof

Customersunknown
Notable
unknown

What the Web Says

OpenDNA offers AI-powered genetic risk assessment tests like CardioRisk+, CancerRisk+, TotalRisk+, and PolyRisk+ to predict and prevent chronic diseases by combining genetic and clinical data. These tests are designed for early risk stratification and personalized prevention, empowering clinicians to integrate results into care plans. The company emphasizes its comprehensive polygenic panels, covering numerous conditions across various disease categories, and the ability to integrate with Electronic Medical Records (EMRs) for seamless clinical workflows.

Overall: Mixed

Strengths

  • Comprehensive polygenic panels covering over 30 complex conditions across eight major disease categories.
  • AI-powered insights combining polygenic risk scores with clinical context for more accurate predictions.
  • Seamless integration into EMRs for automated data pull and real-time decision support.
  • Interactive 'What-If' dashboards for clinicians and patients to adjust risk factors and see impact on lifetime risk.
  • Physician-ordered tests, empowering clinicians to guide interpretation and integrate results into care plans.
  • Clinically validated models integrating polygenic and monogenic risk factors.

Limitations

  • Limited public reviews from individual physicians, healthcare IT, or tech reviewers outside of company-published materials.
  • No reviews found on Reddit, G2, or Capterra specifically for OpenDNA's genetic testing products (CardioRisk+, CancerRisk+, TotalRisk+, PolyRisk+).
  • Potential for a long learning curve and limited documentation, as noted in a general review for a similar product on G2.
  • Concerns about the accuracy and potential for misinformation with AI in healthcare, as expressed on Reddit regarding AI oncologists.
  • The need for additional studies to determine how best to use genetic risk information in clinical decision-making and ensure performance across diverse populations.
  • Risk scores may be primarily derived from populations of European ancestry, potentially limiting applicability to diverse populations.

Based on reviews from: OpenDNA (PolyRisk+: AI-Powered Polygenic Risk Panel), OpenDNA (OpenDNA Technology: AI-Powered Disease Prediction & Prevention), EIN Presswire (OpenDNA Unveils Next-Generation Genetic Tests: PolyRisk+ and an Extended TotalRisk+), OpenDNA (OpenDNA Products: AI-Powered Risk Assessments for Disease Prevention), OpenDNA (TotalRisk+: Polygenic-Monogenic Cancer Risk Assessment), PartnerMD (OpenDNA u2014 Personalized Cardiometabolic Genetic Risk Testing), MIDC (OpenDNA, Israeli company in Maryland, is disrupting preventative medicine), PartnerMD (What Is OpenDNA? What Can It Tell You About Your Heart Health?), EIN Presswire (Encore Concierge Medicine and OpenDNA Announce Strategic Partnership to Offer Advanced AI-Driven Genetic Screening Tests), OpenDNA (News Archives), Capterra (Core dna Software Pricing, Alternatives & More 2026), Capterra (Cardiris 5 Software Pricing, Alternatives & More 2026 | Capterra), G2 (DB Gene Reviews & Product Details), Mass General Brigham (Validation Study from Mass General Brigham Reveals New Tool Can Predict Patients' Genetic Risk of Eight Cardiovascular Conditions), New England Journal of Medicine Journal Watch (Newly Developed Polygenic Risk Scores May Assist Decision-making in Primary Care), Brigham and Women's Hospital (Newly developed genetic risk scores could help patients, physicians make health decisions), Capterra (openDoctor Software Pricing, Alternatives & More 2026 | Capterra), AI in Healthcare (I Built an AI Oncologist to Help Me Navigate Stage IV Pancreatic Cancer. Today Is Day 234.), Capterra (OpenClinica Reviews 2026. Verified Reviews, Pros & Cons | Capterra), Reddit (Anyone have experience with Radical Health? : r/breastcancer)

Last updated: 2026-09-23

Ratings & Reviews

No reviews yet. Be the first to review this tool!

Rate OpenDNA (CardioRisk+, CancerRisk+, TotalRisk+, PolyRisk+)

Clinical Value
Ease of Use
Integration
Support & Docs
Value for Money

Press & Coverage

EIN Presswire
OpenDNA Unveils Next-Generation Genetic Tests: PolyRisk+ and an Extended TotalRisk+
OpenDNA launched PolyRisk+, a polygenic risk score panel, and an extended TotalRisk+, combining polygenic and monogenic information, covering 30 indications across eight major disease categories. These tests provide comprehensive, full-body genetic risk insights for enhanced patient care and are available only through healthcare providers.
2025-07
MIDC (Maryland/Israel Development Center)
OpenDNA, Israeli company in Maryland, is disrupting preventative medicine - MIDC
OpenDNA is integrating genomics, polygenic risk scoring, and AI to predict and prevent chronic diseases, with their approach validated in a July 2025 publication in Frontiers in Genetics. The company has expanded its offerings to cover 32 distinct diseases and secured a commercial agreement with Mayo Clinic Arizona.
2025-07
OpenDNA
Harper Health Partners with OpenDNA to Provide AI-Based Genetic Risk Testing
OpenDNA and Harper Health announced a clinical partnership to integrate OpenDNA's advanced polygenic risk score (PRS) technology into Harper Health's concierge care model. This collaboration offers Harper Health patients insights into their risk for cardiovascular disease, cancer, and other conditions through CardioRisk+, CancerRisk+, and TotalRisk+ tests.
2025-02
EIN Presswire
Encore Concierge Medicine and OpenDNA Announce Strategic Partnership to Offer Advanced AI-Driven Genetic Screening Tests
Encore Concierge Medicine partnered with OpenDNA to offer CardioRisk+, CancerRisk+, and TotalRisk+ tests, which combine AI, genetic insights, and clinical data for precise health risk assessment. This collaboration aims to provide patients with critical insights for proactive, preventative, and personalized healthcare.
2025-03
OpenDNA
Blossom Family Medicine Partners with OpenDNA to Bring Precision Genetic Testing to Primary Care
OpenDNA partnered with Blossom Family Medicine to integrate precision genetic testing into primary care, offering CardioRisk+, CancerRisk+, and TotalRisk+ solutions. These tests combine polygenic risk scoring with clinical and family history to provide personalized health risk assessments and guide prevention strategies.
2025-05
OpenDNA
Clinical Resources - OpenDNA
OpenDNA's clinical resources page highlights peer-reviewed studies on the clinical relevance and impact of polygenic risk scores. It references publications in The New England Journal of Medicine and JAMA Oncology from 2025, supporting the use of their tests like CardioRisk+, CancerRisk+, TotalRisk+, and PolyRisk+.
2025-07
PartnerMD
What Is OpenDNA? What Can It Tell You About Your Heart Health?
OpenDNA analyzes genomic sequences and uses AI to assess risks for heart disease, diabetes, or hypertension by comparing an individual's DNA to those with these conditions. This technology can help individuals over 40 consider if medications and additional steps are necessary to control cardiovascular problems.
2024-07

Videos

Product demos, reviews, and walkthroughs for OpenDNA (CardioRisk+, CancerRisk+, TotalRisk+, PolyRisk+).

Loading videos...

View all on YouTube

Frequently Asked Questions

OpenDNA's CardioRisk+ is designed to integrate with existing EMR systems through standard APIs, allowing for seamless data exchange and incorporation of risk assessments directly into patient records. This aims to minimize disruption to current workflows and provide physicians with readily accessible insights at the point of care.
OpenDNA's AI models, including CardioRisk+ and CancerRisk+, are developed with a focus on regulatory compliance. Specific certifications such as FDA clearance or CE Mark depend on the region of deployment and the classification of the device, and physicians should consult OpenDNA's official documentation for the most up-to-date regulatory status in their jurisdiction.
OpenDNA's risk prediction models are built upon extensive research and validated using large datasets. The clinical validity and utility, especially across diverse patient populations, are supported by internal studies and, where available, peer-reviewed publications. Physicians can request detailed validation reports and information on the demographic representation within the training data.
OpenDNA employs robust data privacy and security measures, adhering to regulations like HIPAA and GDPR, to protect patient health information utilized by TotalRisk+ and PolyRisk+. This includes data encryption, access controls, and anonymization techniques to ensure the confidentiality and integrity of sensitive data.
OpenDNA offers flexible pricing models for its suite of products, which may include subscription-based access, per-use fees, or tiered pricing based on the volume of assessments. Specific pricing structures can vary, and physicians or healthcare institutions should contact OpenDNA directly for detailed quotes and options tailored to their needs.
OpenDNA acknowledges that all AI algorithms have limitations and potential biases, which are carefully studied and documented. These limitations, such as performance variations in specific subgroups or data dependencies, are communicated to physicians through product documentation, training materials, and direct support channels to ensure informed clinical decision-making.
While OpenDNA offers a comprehensive suite of risk assessment tools, physicians may also consider other AI-powered solutions available in the market. These alternatives can vary in their focus, methodology, and integration capabilities, and a thorough review of each option's evidence base and features is recommended to determine the best fit for specific clinical needs.

Related Tools

EchoMD AutoEF
Caption Health (formerly Bay Labs, now part of GE HealthCare)
Cardiology AI
EchoMD AutoEF is an FDA-cleared AI software that automates the selection of echocardiogram clips and calculates left ventricular ejection fraction (EF), enhancing efficiency and accuracy in cardiac assessments.
ECG-AI Cardiac Amyloidosis (CA) 12-Lead Algorithm
Anumana, Inc.
Cardiology AI
An AI algorithm for screening cardiac amyloidosis using standard 12-lead ECGs.
DEEPVESSEL Plaque
Keya Medical Technology Co., Ltd.
Cardiology AI
An AI software platform for coronary plaque analysis and quantification from CT angiography.
WatchMate Software
Anumana, Inc.
Cardiology AI
Anumana is an AI-driven health technology company from nference, developing and delivering ECG algorithms enabling early diagnosis and intervention.
syngo.CT Coronary Cockpit
Siemens Healthineers
Cardiology AI
syngo.CT Coronary Cockpit is an AI-powered software tool by Siemens Healthineers for efficient and accurate CT coronary angiography analysis.
HeartLung AI-CVD®
HeartLung Corporation
Cardiology AI
HeartLung AI-CVD® is an FDA-cleared AI-powered quantitative imaging tool that provides automated CT-derived measurements for assessing cardiovascular and multisystem risks opportunistically.

See all Cardiology AI tools →

Suggest an Edit → | Last Verified: 2026-06-23 | First Added: 2026-06-23
AI Tool Finder
AI-powered search. Results may not be comprehensive.